Open-Label Study of TPI 287 for Patients With Metastatic Melanoma
Status:
Withdrawn
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
The goal of this clinical research study is to find the highest tolerable dose of TPI 287
that can be given to patients with metastatic melanoma. Researchers want to find out if TPI
287 can control the disease. The safety of TPI 287 will also be studied.